摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-溴-6-甲氧基-3-(3-甲基苄基)-1H-吲唑 | 1001195-64-7

中文名称
5-溴-6-甲氧基-3-(3-甲基苄基)-1H-吲唑
中文别名
——
英文名称
5-bromo-6-methoxy-3-(3-methylbenzyl)-1H-indazole
英文别名
5-bromo-6-methoxy-3-[(3-methylphenyl)methyl]-2H-indazole
5-溴-6-甲氧基-3-(3-甲基苄基)-1H-吲唑化学式
CAS
1001195-64-7
化学式
C16H15BrN2O
mdl
——
分子量
331.212
InChiKey
HQVSAUHXQXSOFD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    478.6±40.0 °C(Predicted)
  • 密度:
    1.434±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.5
  • 重原子数:
    20
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.19
  • 拓扑面积:
    37.9
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

点击查看最新优质反应信息

文献信息

  • INDAZOLE DERIVATIVES FOR THE TREATMENT OF HSP90-INDUCED DISEASES
    申请人:Buchstaller Hans Peter
    公开号:US20090197882A1
    公开(公告)日:2009-08-06
    Novel indazole derivatives of the formula (I), in which R 1 -R 3 have the meanings indicated in Claim ( 1 ), are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    式(I)中的新型吲唑衍生物,其中R1-R3具有权利要求书(1)中指示的含义,是HSP90抑制剂,可用于制备用于治疗HSP90起作用的疾病的药物。
  • Indazole derivatives for the treatment of HSP9O-induced diseases
    申请人:Buchstaller Hans-Peter
    公开号:US08722903B2
    公开(公告)日:2014-05-13
    Novel indazole derivatives of the formula (I), in which R1-R3 have the meanings indicated in Claim (1), are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
    式(I)中R1-R3具有权利要求书(1)中所示的含义的新型吲唑衍生物是HSP90抑制剂,可用于制备用于治疗抑制、调节和/或调控HSP90在其中发挥作用的疾病的药物。
  • Fragment-based discovery of hydroxy-indazole-carboxamides as novel small molecule inhibitors of Hsp90
    作者:Hans-Peter Buchstaller、Hans-Michael Eggenweiler、Christian Sirrenberg、Ulrich Grädler、Djordje Musil、Edmund Hoppe、Astrid Zimmermann、Harry Schwartz、Joachim März、Jörg Bomke、Ansgar Wegener、Michael Wolf
    DOI:10.1016/j.bmcl.2012.04.121
    日期:2012.7
    Inhibitors of the Hsp90 molecular chaperone are showing considerable promise as potential molecular therapeutic agents for the treatment of cancer. Here we describe the identification of novel small molecular weight inhibitors of Hsp90 using a fragment based approach. Fragments were selected by docking, tested in a biochemical assay and the confirmed hits were crystallized. Information gained from X-ray structures of these fragments and other chemotypes was used to drive the fragment evolution process. Optimization of these high mu M binders resulted in 3-benzylindazole derivatives with significantly improved affinity and anti-proliferative effects in different human cancer cell lines. (C) 2012 Elsevier Ltd. All rights reserved.
  • INDAZOLDERIVATE ZUR BEHANDLUNG VON HSP90-INDUZIERTEN KRANKHEITEN
    申请人:Merck Patent GmbH
    公开号:EP2035391B1
    公开(公告)日:2011-11-23
  • INDAZOLAMIDDERIVATE
    申请人:Merck Patent GmbH
    公开号:EP2155690B1
    公开(公告)日:2011-08-03
查看更多